Skip to main content
NewslettersWatchlist

Geovax Labs Inc WT(GOVXW-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.0400
Day High0.0600
Open:0.0600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Globe Newswire
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update
Globe Newswire
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
Globe Newswire
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
Globe Newswire
GeoVax to Present at BIO International Convention 2022
Globe Newswire
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
Globe Newswire
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China
Globe Newswire
GeoVax Announces Upcoming Presentations at Scientific Conferences
Globe Newswire
GeoVax Announces Issuance of Malaria Vaccine Patent
Globe Newswire
GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update
Globe Newswire
CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
Globe Newswire
Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
Globe Newswire
GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress
Globe Newswire
GeoVax Announces Issuance of Cancer Vaccine Patent
Globe Newswire
GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022
Globe Newswire
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
Globe Newswire
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2
Globe Newswire
GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update
Globe Newswire
GeoVax Announces Key Staff Appointments
Globe Newswire
GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update
Globe Newswire
GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100
Globe Newswire
GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference
Globe Newswire
GeoVax Announces Closing of $10 Million Private Placement
Globe Newswire
GeoVax Announces $10 Million Private Placement
Globe Newswire
GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial
Globe Newswire
GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer
Globe Newswire
GeoVax Issues Shareholder Update Letter
Globe Newswire
GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster
Globe Newswire
GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress
Globe Newswire
GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress
Globe Newswire
GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress
Globe Newswire
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent
Globe Newswire
GeoVax Announces Upcoming Presentations at Scientific Conferences

Profile

GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.